Sarepta Therapeutics (SRPT) Debt to Equity (2010 - 2026)

Sarepta Therapeutics' Debt to Equity history runs 17 years deep, the most recent figure standing at $0.56 for Q1 2026.

• In Q1 2026, Debt to Equity fell 44.1% year-over-year to $0.56; the TTM figure through Mar 2026 stood at $0.56 (down 44.1% YoY), while the FY2025 annual figure was $0.73, down 2.36% from the prior year.
• Debt to Equity was $0.56 for Q1 2026 at Sarepta Therapeutics, down from $0.73 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $4.01 in Q4 2022 to a low of $0.56 in Q1 2026.
• Historically, Debt to Equity has averaged $1.47 across 5 years, with a median of $1.28 in 2022.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity soared 239.41% in 2022, then plunged 64.09% in 2023.
• A 5-year view of Debt to Equity shows it stood at $4.01 in 2022, then slumped by 64.09% to $1.44 in 2023, then sank by 48.33% to $0.74 in 2024, then fell by 2.36% to $0.73 in 2025, then retreated by 23.38% to $0.56 in 2026.
• The last three Debt to Equity figures came in at $0.56 (Q1 2026), $0.73 (Q4 2025), and $0.81 (Q3 2025), per Business Quant data.